Tesi fation, Andeberhan; Zecarias, Alem; Zewengiel, Solomon; Willis, Rebecca; Mebrahtu, Goitom; Capa, Eva; Mpyet, Caleb; Al-Khatib, Tawfik; Courtright, Paul; Solomon, Anthony W; Aboe, Agatha; Adamu, Liknaw; Al-Khatib, Tawfik; Alemayehu, Wondu; Alemu, Menbere; Alexander, Neal DE; Bakhtiari, Ana; Bero, Berhanu; Boisson, Sophie; Bovill, Sarah; Brooker, Simon J; Bush, Simon; Chu, Brian K; Courtright, Paul; Dejene, Michael; Emerson, Paul M; Flueckiger, Rebecca M; Foster, Allen; Gadisa, Solomon; Gass, Katherine; Gerebre, Teshome; Habtamu, Zelalem; Haddad, Danny; Harvey, Erik; Haslam, Dominic; Kalua, Khumbo; Kello, Amir B; King, Jonathan D; Le Mesurier, Richard; Lewallen, Susan; Lietman, Thomas M; MacArthur, Chad; Macleod, Colin; Mariotti, Silvio P; Massae, Patrick A; Massey, Anna; Mathieu, Els; McCullagh, Siobhain; Mekasha, Addis; Millar, Tom; Mpyet, Caleb; Munoz, Beatriz; Ngondi, Jeremiah; Ogden, Stephanie; Pavluck, Alex; Pearce, Joseph; Resnikoff, Serge; Sarah, Virginia; Sarr, Boubacar; Sisay, Alemayehu; Smith, Jennifer L; Solomon, Anthony W; Thomson, Jo; West, Sheila K; Willis, Rebecca (2018) Progress Towards Elimination of Trachoma as a Public Health Problem in Eritrea: Results of a Systematic Review and Nine Population-based Prevalence Surveys Conducted in 2014. OPHTHALMIC EPIDEMIOLOGY, 25 (sup1). pp. 121-130. ISSN 0928-6586 DOI: https://doi.org/10.1080/09286586.2018.1545036

Downloaded from: http://researchonline.lshtm.ac.uk/4651140/

DOI: 10.1080/09286586.2018.1545036

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Progress Towards Elimination of Trachoma as a Public Health Problem in Eritrea: Results of a Systematic Review and Nine Population-based Prevalence Surveys Conducted in 2014

Andeberhan Tesfazion, Alem Zecarias, Solomon Zewengiel, Rebecca Willis, Goitom Mebrahtu, Eva Capa, Caleb Mpyet, Tawfik Al-Khatib, Paul Courtright, and Anthony W. Solomon, for the Global Trachoma Mapping Project

ABSTRACT

Purpose: To assess Eritrea’s progress towards elimination of trachoma as a public health problem, we reviewed and compiled current knowledge on the distribution and burden of trachoma in Eritrea, then undertook further population-based surveys where indicated, with support from the Global Trachoma Mapping Project (GTMP).

Methods: For the systematic review, undertaken in March 2014, we searched (1) PubMed, using the terms (blind or trachoma or trichiasis) AND Eritrea; (2) the online database of rapid assessments of avoidable blindness; (3) our own grey literature collections; and (4) the Global Atlas of Trachoma database. In June and July 2014, we conducted nine population-based prevalence surveys, for each of which 30 villages were systematically selected with probability proportional to population size; in each village, 30 households were systematically selected. All consenting residents of selected households aged ≥1 year were examined by GTMP-certified graders for signs of trachoma. Data on household-level access to water and sanitation were also collected.

Results: One previous rapid assessment of avoidable blindness, three peer-reviewed publications, and two grey literature reports detailing sets of trachoma prevalence surveys conducted in 2006 and 2011, respectively, were located. Post-intervention impact surveys were needed in seven evaluation units (EUs, framed at sub-Zoba-level: population range 40,000–120,000) of Debub and Northern Red Sea, while baseline surveys were needed in two EUs of Anseba. Four of the seven impact survey EUs and both baseline survey EUs returned trachomatous inflammation—follicular prevalences in 1–9-year-olds of ≥5%; six of the seven impact survey EUs and one of the two baseline survey EUs returned trichiasis prevalences in ≥15-year-olds of ≥0.2%. The prevalence of access to water and sanitation varied widely between EUs.

Conclusion: Interventions are still required in Eritrea to eliminate trachoma as a public health problem. Data from these surveys will guide the Ministry of Health to undertake programme planning using a sound evidence base.

Introduction

Trachoma is an eye disease caused by particular strains of the bacterium *Chlamydia trachomatis*. It is strongly associated with poverty. In 2016, approximately 190 million people were thought to live in endemic areas globally, where transmission of *C. trachomatis* from eye to eye is believed to occur via eye-seeking flies, fingers and fomites. Recurrent episodes of active (inflammatory) trachoma in children can produce trachoma’s blinding complication, trichiasis, in later life.

The World Health Organization (WHO) defines “elimination of trachoma as a public health problem” as a prevalence of the active trachoma sign “trachomatous inflammation—follicular” (TF) among 1–9-year-olds
olds of <5%, and a prevalence of trichiasis unknown to the health system\textsuperscript{10} among ≥15-year-olds of <0.2%, in every previously-endemic district.\textsuperscript{11} Achieving this worldwide would constitute the Global Elimination of Trachoma as a public health problem, which is targeted for completion by the end of the year 2020 (GET2020).\textsuperscript{12,13}

Trachoma is recognized to be an endemic disease in Eritrea.\textsuperscript{14} Located in the Horn of Africa, the country is bordered by the Red Sea to the east, Djibouti to the south-east, Ethiopia\textsuperscript{15,16} to the south, and Sudan\textsuperscript{17} to the north and west. It is divided into six regions (Zobas) and has an estimated total population of 3.8 million people. Zobas are divided into a total of 58 districts (sub-Zobas), each of which has a population of 40,000–120,000 people.

WHO recommends that surveys to determine whether or not public-health-level interventions are needed against trachoma normally be conducted in evaluation units (EUs) of 100,000–250,000 people. (This usually corresponds to the unit of administration for healthcare.)\textsuperscript{10} WHO further recommends that baseline surveys may be done in larger EUs than this, in order to get programmes started.\textsuperscript{10} Prior to 2014, some baseline trachoma surveys had already been completed in Eritrea, and interventions had been ongoing since 2011 in eight sub-Zobas.

The purpose of this work, undertaken in 2014, was to review and compile current knowledge on the distribution and burden of trachoma in Eritrea, then to conduct population-based surveys where indicated, with support from the Global Trachoma Mapping Project.\textsuperscript{18–21} In each EU that needed to be surveyed, we used internationally-standardized approaches to determine the prevalence of trichiasis in adults aged ≥15 years, the prevalence of TF in children aged 1–9 years, and prevalence of access to improved water and sanitation.\textsuperscript{22}

Methods

We undertook work in two phases. First, we carried out a systematic review to consolidate what was already known about the epidemiology of trachoma in Eritrea. A PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) search was conducted for articles containing information on trachoma epidemiology in the country, published in any language prior to the search date of 7 March 2014. We used search terms ("blind" or trachoma or trichiasis) AND Eritrea). We supplemented this with a search of the online database of rapid assessments of avoidable blindness (http://raabdata.info/repository/), review of relevant grey literature held by the authors, and review of the data from Eritrea held by the Global Atlas of Trachoma (www.trachomaatlas.org\textsuperscript{23,24}) as of 7 March 2014.

Second, guided by the results of the first phase, we implemented a series of cross-sectional surveys using two-stage cluster sampling in a total of nine EUs: seven sub-Zobas of Debub and Northern Red Sea (where impact surveys were due) and two EUs in Anseba Zoba (where sufficiently detailed baseline data were not available: see below).

Sample size

Sample-size calculations were determined based on TF considerations, as recommended by WHO.\textsuperscript{25} The EU-level sample size for baseline surveys is based on an expected TF prevalence in 1–9-year-olds of 10% and desired absolute precision of 3%. Using the single-population-proportion-for-precision formula\textsuperscript{26} with a design effect of 2.65, to have 95% confidence of estimating a prevalence of 10% ± 3%, 1019 children are needed.\textsuperscript{19} The EU-level sample size for impact surveys is based on an expected TF prevalence in 1–9-year-olds of 4% and desired absolute precision of 2%.\textsuperscript{10} Using the same formula and a design effect of 2.65, to have 95% confidence of estimating a prevalence of 4% ± 2%, 978 children are needed. Inflating these figures by a factor of 1.2 to account for non-response, we aimed to sample enough households to be able to enumerate 1222 resident children (baseline EUs) or 1174 resident children (impact survey EUs).

Sampling plan

The first-stage sampling units were villages (population range 100–1000 people). The sampling frame was the list of all villages obtained from Eritrea’s Ministry of Local Government; 30 were systematically selected, with probability that was proportional to village population size.\textsuperscript{25} In each selected village, 30 households were selected, as follows. In small villages, the list of households was obtained from village administrators and households were systematically selected. In large villages, four zones were created, one zone was drawn at random, then the small-village selection method was undertaken. Although children aged 1–9 years and adults aged ≥15 years were the age groups of interest, to enhance community acceptability, reduce the amount of explanation that field teams had to provide, and avoid creating incentives for age misrepresentation, in selected households, we included all residents aged ≥1 year.
Team training and data collection

Survey teams comprised one ophthalmic clinical officer, one recorder and one driver. Team preparation was undertaken in accordance with version 2 of the standard GTMP training system. All residents aged ≥1 year in sampled households were enumerated and asked to agree to be examined for signs of trachoma. Household-level data on location (using GPS coordinates) and access to water and sanitation were also recorded. Teams moved from one selected household to the next. Findings were recorded in LINKS-GTMP on Android smartphones.

Data management

Data were encrypted and uploaded to a cloud-based server, and managed according to standard GTMP protocols, as previously described. However, because available census data provided age breakdowns only in 5-year age bands, we initially undertook age standardization of TF prevalence estimates using age bins of 1–4 and 5–9 years, and the assumption that 1–4-year-olds comprise 80% of the 0–5-year-old population. For the purposes of this publication, we have also undertaken age standardization of TF prevalence estimates using 1-year age bands, as employed elsewhere. In each case, the proportion of 1–9 year-olds with TF in each village was adjusted using the relevant age bands. Similarly, the proportion of ≥15-year-olds with trichiasis was adjusted in 5-year age and gender bands. These adjustments were intended to partially compensate for incomplete examination recruitment in different age and gender groups. EU-level prevalence estimates of TF and trichiasis were calculated as the arithmetic means of adjusted village-level proportions of TF and trichiasis, respectively.

Ethical considerations

Informed written consent was obtained from the head of the household to enter and work in each compound. Owing to low levels of literacy and in accordance with local norms, informed verbal consent was obtained for examination. Examiners cleaned their hands with alcohol-based hand gel between each examination, to avoid transferring pathogens between examinees. Individuals with conjunctivitis were treated with 1% tetracycline eye ointment. Individuals needing trichiasis surgery were referred to the Zoba or sub-Zoba hospital where they were offered management by the resident ophthalmologist, ophthalmic officer or trichiasis surgeon. Other medical problems were managed in the field or referred, as appropriate. Each work was conducted in accordance with the principles of the Declaration of Helsinki. Approval was obtained from the ethics committee of the London School of Hygiene & Tropical Medicine (6319 and 8355) and the Eritrea Ministry of Health National Ethics Committee.

Results

Systematic review

Our PubMed search returned 14 papers, only one of which provided data on prevalence of trachoma generated since the 1987 publication of the WHO simplified trachoma grading system. (The same study was also found in the database of rapid assessments of avoidable blindness, as the only Eritrea-related work stored there.) In 2008, Müller et al deployed survey teams to 66 villages systematically selected with probability proportional to village size from a list of all villages in Eritrea. Compact segment sampling was used to select 50 people aged ≥50 years in each village. Amongst 3163 people examined, 386 (12.3%) were bilaterally blind or severely visually impaired; 4 (1.0%) of these had their loss of vision attributed to trachoma.

Two earlier published papers, published in 1963 and 1964, held some data on trachoma that may now be of only limited value, by virtue of their epidemiological power and/or vintage. In 1963, Renna reported results of investigations in the Eastern lowlands of Eritrea in an area surrounding Massaua; the MacCallan trachoma grading system was used to evaluate 485 1–4-year-olds and 1098 5–14-year-olds, finding signs of active trachoma in 194 (40%) and 411 (37%) of those groups, respectively. Vozza et al. completed a survey in 1960 in 10 villages of Serayé, a former province of Eritrea that in the 1996 reclassification was divided by the border created between the Zobas of Debub and Gash-Barka. They found one or more signs of trachoma in 97% of 5015 persons examined; the prevalence of trichiasis in the all-ages population was estimated to be 7%.

Our own grey literature collections included reports of two tranche of trachoma prevalence surveys. In 2006, the Eritrea Ministry of Health undertook trachoma surveys in Debub, Gash-Barka, and Northern Red Sea. A total of three EUs were surveyed, with each one framing the entirety of a Zoba. In each EU, 30 households were enrolled from each of 20 villages. Results are shown in Table 1 and Figure 1. These surveys were adequately powered for making decisions regarding intervention at EU level;
further division of the data (to calculate 12, 14 and nine sub-Zoba-level prevalence estimates for Debub, Gash-Barka and Northern Red Sea, respectively) probably introduces excessive imprecision, and those estimates are therefore not reported here. It is important to note, however, that on the basis of those calculations, one sub-Zoba of Debub (May-Mine, bordering Tigray Region of Ethiopia\(^\text{15}\) to the south) was deemed to have a TF prevalence in 1–9-year-olds of >30%.

Interventions against trachoma, including mass distribution of the antibiotic azithromycin, were undertaken from 2011 to 2013 in all eight sub-Zobas of Debub and Northern Red Sea thought to have TF prevalence ≥10%, based on the 2006 survey data.\(^\text{35}\) By 2014, impact surveys were needed in seven of the eight; the other (May-Mine) was already programmed for two further years of intervention before an impact survey was due.

The second tranche of surveys was conducted by the Ministry of Health in 2011 in the remaining three Zobas (Anseba, Maekel and Southern Red Sea [SRS]), surveyed as a single [discontinuous] evaluation unit composed of all three zobas).

---

**Table 1.** Sampling details and prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds and trichiasis in ≥15-year-olds, Ministry of Health trachoma surveys, Eritrea, 2006.\(^\text{35}\)

<table>
<thead>
<tr>
<th>Zoba</th>
<th>Number of villages (households) sampled</th>
<th>Number examined</th>
<th>TF prevalence, % (95% CI)</th>
<th>Number examined</th>
<th>Trichiasis prevalence, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debub</td>
<td>20 (600)</td>
<td>952</td>
<td>14.9 (12.7–17.4)</td>
<td>1198</td>
<td>2.2 (1.5–3.2)</td>
</tr>
<tr>
<td>Gash-Barka</td>
<td>20 (604)</td>
<td>1125</td>
<td>2.4 (1.6–3.5)</td>
<td>1270</td>
<td>1.9 (1.3–2.9)</td>
</tr>
<tr>
<td>NRS</td>
<td>20 (601)</td>
<td>841</td>
<td>5.5 (4.1–7.3)</td>
<td>1046</td>
<td>1.1 (0.6–1.9)</td>
</tr>
</tbody>
</table>

\(^{a}\)Unadjusted (original datasets unavailable).
CI, confidence interval; NRS, Northern Red Sea.

---

**Figure 1.** Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, trachoma prevalence surveys, Eritrea, 2006 (Debub, Gash-Barka, and Northern Red Sea [NRS], each surveyed as a separate evaluation unit) and 2011 (Anseba, Maekel, and Southern Red Sea [SRS], surveyed as a single [discontinuous] evaluation unit composed of all three zobas).
that the equivalent trichiasis prevalence estimate in ≥15-year-olds for this EU would be 0.6%. It is noted that the proportion of children examined who had TF, and the proportion of adults examined who had trichiasis, were both considerably higher in Anseba than in the other two Zobas. We therefore planned further baseline surveys in Anseba, as part of our second phase of work.

**Global Trachoma Mapping Project surveys**

We undertook survey fieldwork in June–July 2014 in the nine sub-zobas identified to need trachoma prevalence surveys: two repeat baseline surveys in Anseba, six impact surveys in Debub, and one impact survey in Northern Red Sea. Across the nine EUs, 8059 households were visited, and a total of 10,338 1–9-year-olds and 17,056 ≥15-year-olds were enumerated. Of these, 9956 (96%) and 13,926 (82%), respectively, were examined (Table 3). The EU-level prevalence of TF in 1–9-year-olds ranged from 1.6% (95% CI 0.8–2.6) to 9.2% (95% CI 6.6–12.2) (Table 3, Figure 2). The EU-level prevalence of trichiasis in ≥15-year-olds ranged from 0.10% (95% CI 0.00–0.26) to 1.15% (95% CI 0.73–1.66) (Table 3, Figure 3).

There was considerable variation between EUs in the prevalence of household-level access to water and sanitation (Table 4).

**Discussion**

Trachoma is still a public health problem in parts of Eritrea. Both EUs of Anseba (a Zoba previously surveyed in 2011 as part of a large, three-zoba EU)

---

**Table 2.** Sampling details and prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds and trichiasis in ≥40-year-olds, Ministry of Health trachoma surveys, Eritrea, 2011.\(^{36}\)

<table>
<thead>
<tr>
<th>Evaluation unit</th>
<th>Number of villages (households) sampled</th>
<th>Number examined</th>
<th>TF prevalence, % (95% CI)</th>
<th>Number examined</th>
<th>Trichiasis prevalence, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anseba</td>
<td>7 (not stated)</td>
<td>452</td>
<td>3.8 (2.8–4.9)</td>
<td>169</td>
<td>1.5 (0.4–2.9)</td>
</tr>
<tr>
<td>Maekel</td>
<td>10 (not stated)</td>
<td>500</td>
<td>1.5 (0.4–2.9)</td>
<td>170</td>
<td>0.26 (0.00–0.53)</td>
</tr>
<tr>
<td>SRS</td>
<td>3 (not stated)</td>
<td>183</td>
<td>1.5 (0.4–2.9)</td>
<td>144</td>
<td>0.85 (0.29–1.41)</td>
</tr>
<tr>
<td>Total</td>
<td>20 (595)</td>
<td>1135</td>
<td></td>
<td>453</td>
<td></td>
</tr>
</tbody>
</table>

\(^{a}\)Unadjusted (original datasets unavailable).  
\(^{b}\)Adjusted for gender and age in 5–year age bands (see text).  
\(^{c}\)Adjusted for age against the age bands 1–4 years and 5–9 years (see text).  
\(^{d}\)Adjusted for age in 5–year age bands (see text).  
\(^{e}\)CI, confidence interval; N/A, not applicable.

---

**Table 3.** Number of 1–9-year-olds and number of ≥15-year-olds resident, examined, absent and refused; prevalence of trachomatous inflammation—follicular (TF); and prevalence of trichiasis; trachoma prevalence surveys, Eritrea, June and July, 2014.

<table>
<thead>
<tr>
<th>Evaluation unit</th>
<th>Number of villages (households) sampled</th>
<th>Number examined</th>
<th>TF prevalence, % (95% CI)</th>
<th>Number examined</th>
<th>Abdominal prevalence, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anseba, Adi</td>
<td>31</td>
<td>1380</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Tekelizian/</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elabaried/Gheleb/Hagaz (1)</td>
<td></td>
<td>1279</td>
<td>8.5 (5.9–11.0)</td>
<td>2086</td>
<td>0.44 (0.14–0.74)</td>
</tr>
<tr>
<td>Anseba, Habero/</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halhal/</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamelmalo/Keren (2)</td>
<td></td>
<td>1176</td>
<td>8.2 (5.5–10.5)</td>
<td>2086</td>
<td>0.44 (0.14–0.74)</td>
</tr>
<tr>
<td>Debub, Adi Quala (3)</td>
<td></td>
<td>1032</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Debub, Areza (4)</td>
<td></td>
<td>1012</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Debub, Dubarwa (5)</td>
<td></td>
<td>1097</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Debub, Emni Halli (6)</td>
<td></td>
<td>1547</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Debub, Mendefera (7)</td>
<td></td>
<td>1019</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Debub, Sena’fe (8)</td>
<td></td>
<td>858</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Northern Red Sea, Nakfa (9)</td>
<td></td>
<td>1115</td>
<td>8.6 (6.1–11.4)</td>
<td>2282</td>
<td>0.15 (0.06–0.27)</td>
</tr>
<tr>
<td>Totals</td>
<td>270</td>
<td>10,338</td>
<td>8.6 (6.1–11.4)</td>
<td>17,056</td>
<td>0.15 (0.06–0.27)</td>
</tr>
</tbody>
</table>

\(^{a}\)Adjusted for age in 1–year age bands (see text).  
\(^{b}\)Adjusted for age against the age bands 1–4 years and 5–9 years (see text).  
\(^{c}\)Adjusted for gender and age in 5–year age bands (see text).  
\(^{d}\)CI, confidence interval; N/A, not applicable.
returned 2014 baseline TF prevalence estimates in 1–9-year-olds indicating a need for intervention with the A, F and E components of the SAFE strategy.\textsuperscript{38,39} One of those two Anseba EU’s also had a trichiasis prevalence in adults above the 0.2% elimination threshold, and will therefore need public-health-level implementation of the S component of SAFE.\textsuperscript{11} Of the seven EU’s in which we completed impact surveys, three had TF prevalences <5% and now enter the two-year active trachoma surveillance period\textsuperscript{11,46} while the other four require ongoing A, F and E interventions. Only one of the seven impact survey EU’s (Nafka sub-Zoba of Northern Red Sea) had a trichiasis prevalence in adults <0.2%.

Figure 2. Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, trachoma prevalence surveys, June and July, 2014. Sub-Zobas are labelled with numbers; the key is found in both Tables 3 and 4. (NRS, Northern Red Sea; SRS, Southern Red Sea).

Figure 3. Prevalence of trichiasis in ≥15-year-olds, trachoma prevalence surveys, Eritrea, June and July, 2014. Sub-Zobas are labelled with numbers; the key is found in both Tables 3 and 4. (NRS, Northern Red Sea; SRS, Southern Red Sea).
Because available Eritrea census publications report age-specific data for the bands 1–4 and 5–9 years, we initially undertook age standardization of TF estimates against those two broad divisions. Elsewhere in similar circumstances, the GTMP developed a practice of evenly sub-dividing such totals into one-year age bands and age-standardizing against the result, using the rationale that ignoring mortality from 12 to 59 months and from 60 to 119 months would be preferable to ignoring the (often substantial) differences in age-specific TF prevalence within these age brackets. We therefore undertook repeat analysis using one-year age band standardization for the purposes of compiling this manuscript. For Areza and Dubarwa sub-Zobas in Debub, standardizing against broader and finer age bands gave programmatically different TF prevalence estimates. For both EUs, the TF prevalence was determined to be within the 5.0–9.9% range using the finer age bands, and just greater than 10% using the broader ones. Although the confidence intervals for these paired alternate estimates had considerable overlap, the distinctions are functionally important, because EUs in which TF prevalence is 10.0–29.9% qualify for three years of annual mass antibiotic treatment, whereas WHO recommends only that targeted antibiotic treatment be considered in EUs in which TF prevalence is 5.0–9.9%. (Recent data suggest that a single round of mass treatment may be effective for EUs in that prevalence range.) Further work to determine the most appropriate way to undertake age standardization of TF prevalence estimates may be needed.

The data reported here have other deficiencies. We did not examine for the presence or absence of trachomatous scarring in tarsal conjunctivae of eyes with trichiasis. The extremely high proportion of resident children apparently examined (Table 3) suggests that field teams either enumerated only those present at the time of the visit or were assiduous in returning at the end of the day to examine children who were initially absent; our field supervisors believe the latter explanation is correct. (This belief is supported by the fact that many absentee adults were enumerated.) In Sena’fe sub-Zoba, only 858 1–9-year-olds were examined: 88% of the 978 targeted, though availability of data from 30 (rather than fewer) clusters and the relatively tight confidence intervals suggest that the TF prevalence estimate here would be reproducible. There were large differences in the numbers of absentee adults recorded between EUs, an observation for which we also lack a definitive explanation. Finally, GPS satellite fixes were frequently elusive, and many houses therefore lacked GPS coordinate information, limiting our ability to quality-assure household selection.

These were not easy surveys. First, selected villages were often very hard to reach, with terrain that did not allow vehicle access. Field teams were forced to start work early and travel on foot for several hours to reach the villages of interest. Second, delays occasioned by difficulties in transferring financial resources into the country meant that fieldwork commenced at the onset of the rainy season. Potential examinees were therefore busy with time-sensitive planting activities, and our graders and recorders had to find them in nearby fields. These timing issues made making return visits to households (to find people absent at the time of the first visit) a challenge. Third, crippling power shortages and limited bandwidth complicated the process of data upload-to-cloud in Asmara. We are proud of the commitment of our teams in having successfully completed the work despite these hurdles.

There remain a few sub-Zobas from the 2006 baseline surveys in which TF or trichiasis prevalence estimates were calculated (with wide confidence intervals, based on relatively few sampled clusters) to be above elimination thresholds. Eventually, to facilitate completion of a dossier claiming elimination of trachoma as a public health

### Table 4. Household-level access to improved water and sanitation facilities by evaluation unit, trachoma prevalence surveys, Eritrea, June and July, 2014.

<table>
<thead>
<tr>
<th>Evaluation unit (Zoba, sub-Zoba [i]) (label in Figures 2 and 3)</th>
<th>Number of households enrolled, n</th>
<th>Access to (any source of) water for face-washing within a 30-minute round trip, %</th>
<th>Access to an improved source of drinking water, %</th>
<th>Access to improved sanitation, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anseba, Adi Kelelezan/Elabared/ Gheleb/Hagaz (1)</td>
<td>925</td>
<td>70</td>
<td>80</td>
<td>46</td>
</tr>
<tr>
<td>Anseba, Habero/Halhal/ Hamelmalo/Keren (2)</td>
<td>870</td>
<td>77</td>
<td>54</td>
<td>29</td>
</tr>
<tr>
<td>Debub, Adi Quala (3)</td>
<td>901</td>
<td>79</td>
<td>76</td>
<td>3</td>
</tr>
<tr>
<td>Debub, Arena (4)</td>
<td>891</td>
<td>63</td>
<td>43</td>
<td>11</td>
</tr>
<tr>
<td>Debub, Dubarwa (5)</td>
<td>894</td>
<td>54</td>
<td>65</td>
<td>91</td>
</tr>
<tr>
<td>Debub, Emni Haili (6)</td>
<td>902</td>
<td>58</td>
<td>17</td>
<td>1</td>
</tr>
<tr>
<td>Debub, Mendefera (7)</td>
<td>873</td>
<td>61</td>
<td>38</td>
<td>20</td>
</tr>
<tr>
<td>Debub, Sena’fe (8)</td>
<td>900</td>
<td>80</td>
<td>50</td>
<td>53</td>
</tr>
<tr>
<td>Northern Red Sea, Nakfa (9)</td>
<td>903</td>
<td>69</td>
<td>57</td>
<td>3</td>
</tr>
</tbody>
</table>
problem from Eritrea, it may be necessary to re-survey these sub-Zobas. Repeat surveys will also be necessary to ensure that trachoma has been eliminated from EUs in which more precisely estimated prevalence estimates suggest that trachoma remains a public health problem. The priority for this round of surveys was to undertake baseline mapping in Anseba and to carry out the impact surveys in Debub and Northern Red Sea. Completion of the systematic review and nine population-based prevalence surveys described here provides a check-in point for ongoing efforts to eliminate trachoma from Eritrea. Such efforts are an important part of the global programme, which is now, following decades of work, starting to meet with success.45

Disclosure statement
None of the authors have any proprietary or conflict of interest with this submission. The authors alone are responsible for the writing and content of this article.

Funding
The systematic review and baseline surveys described here were principally funded by the Global Trachoma Mapping Project (GTMP) grant from the United Kingdom’s Department for International Development (DFID; ARIES: 203145) to Sightsavers, which led a consortium of non-governmental organizations and academic institutions to support health ministries to complete baseline trachoma mapping worldwide. The GTMP was also funded by the United States Agency for International Development (USAID), through the ENVISION project implemented by RTI International under cooperative agreement number AID-OAA-A-11-00048, and the END in Asia project implemented by FHI360 under cooperative agreement number OAA-A-10-00051. A committee established in March 2012 to examine issues surrounding completion of global trachoma mapping was initially funded by a grant from Pfizer to the International Trachoma Initiative. AWS was a Wellcome Trust Intermediate Clinical Fellow (098521) at the International Trachoma Initiative. AWS was now a staff member of the World Health Organization.

Impact surveys were funded by the Fred Hollows Foundation (FHF).

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. Other than the personal input of EC, who contributed as a study investigator whilst employed by FHF (and is therefore a co-author of this article), none of the funders had any role in project design, in project implementation or analysis or interpretation of data, in the decisions on where, how or when to publish in the peer reviewed press, or in preparation of the manuscript.

References


**Appendix**

The authors are grateful to the following for their diligent contributions in the field for the 2014 surveys: Ghebre Hailemicael, Mehari Tekle, Mehari Semereab, Bisrat Woldeghiorgis, Yohannes Zehaye, Hussien Abdela, Samuel Kebede, and Ye bio Ghebreab (Graders); Fessha Zerai, Tesfagabir Akale, Semir Abdu Talke, Fesha Teame, Aman Goitom, Hailemicael Hagos, Goitom Habtemariam, and Ghebrehiwet Arefaine (Recorders); and Micael Teklai, Feshaye Ghergis, and Ghebreselasie Ghebremariam (Facilitators).

The Global Trachoma Mapping Project Investigators are: Agatha Aboe (1,11), Liknaw Adamu (4), Tawfik Al-Khatib (5), Wondu Alemayehu (4,5), Menbere Alemu (4), Neal D. E. Alexander (9), Ana Bakhtiari (2,9), Berhanu Bero (4), Sophie Boisson (3), Sarah Bovill (8), Simon J. Brooker (1,6), Simon Bush (7,8), Brian K. Chu (2,9), Paul Courtright (1,3,4,7,11), Michael Dejene (3), Paul M. Emerson (1,6,7), Rebecca M. Flueckiger (2), Allen Foster (1,7), Solomon Gadisa (4), Katherine Gass (6,9), Teshome Gebre (4), Zelalem Habtamu (4), Danny Haddad (1,6,7,8), Erik Harvey (1,6,10), Dominic Haslam (8), Khumbo Kalua (5), Amir B. Kello (4,5), Jonathan D. King (6,10,11), Richard Le Mesurier (4,7), Susan Lewallen (4,11), Thomas M. Lietman (10), Chad MacArthur (6,11), Colin Macleod (3,9), Silvio P. Mariotti (7,11), Patrick A. Massae (5), Anna Massey (8), Els Mathieu (6,11), Siobhain McCullagh (8), Addis Mekasha (4), Tom Millar (4,8), Caleb Mpyet (3,5), Beatriz Muñoz (6,9), Jeremiah Ngondi (1,3,6,11), Stephanie Ogden (6), Alex Pavluck (2,4,10), Joseph Pearce (10), Serge Resnikoff (1), Virginia Sarah (4), Boubacar Sarr (5), Alemayehu Sisay (4), Jennifer L. Smith (11), Anthony W. Solomon (1,2,3,4,5,6,7,8,9,10,11), Jo Thomson (4); Sheila K. West (1,10,11), Rebecca Willis (2,9).